Literature DB >> 28248753

Update on the risks of benign adrenocortical incidentalomas.

Guido Di Dalmazi1.   

Abstract

PURPOSE OF REVIEW: Recent studies highlighted the association between adrenocortical incidentalomas and several comorbidities. This review summarizes the most recent evidence showing the potential risks related to adrenocortical tumors classified as nonfunctioning adrenal incidentalomas (NFAIs) or associated with clinically autonomous cortisol secretion (ACS). RECENT
FINDINGS: Alterations in glucose metabolism are a common finding in patients with ACS (30% of the cases). As shown in nonrandomized trials, surgical treatment may improve or cure diabetes in 52% of patients. Cross-sectional studies showed that NFAIs are also associated with insulin resistance. In a recent long-term retrospective study, patients with NFAI were at increased risk of developing prediabetes/diabetes during follow-up. Similarly, a prospective study showed that the incidence of prediabetes was higher also in tumors converting from NFAI to ACS. Patients with ACS are at increased risk of cardiovascular events and related mortality. Some cardiovascular markers were altered in patients with NFAI, even if a cause-effect relationship is not readily evident. Finally, 13% of NFAIs have increased risk of developing ACS during long-term follow-up.
SUMMARY: Patients with NFAI are at increased risk of developing alterations of glucose metabolism, whereas those with ACS or NFAI who converted to ACS over time are at risk for cardiovascular diseases.

Entities:  

Mesh:

Year:  2017        PMID: 28248753     DOI: 10.1097/MED.0000000000000341

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  3 in total

1.  Increased mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: a 13-year retrospective study from one center.

Authors:  Jekaterina Patrova; Magnus Kjellman; Hans Wahrenberg; Henrik Falhammar
Journal:  Endocrine       Date:  2017-09-08       Impact factor: 3.633

2.  MIFEPRISTONE TREATMENT FOR MILD AUTONOMOUS CORTISOL SECRETION DUE TO ADRENAL ADENOMAS: A PILOT STUDY.

Authors:  Regina Belokovskaya; Aarti Ravikumar; Dushyanthy Arumugam; Sudeh Izadmehr; Gillian M Goddard; Eliza B Geer; Alice C Levine
Journal:  Endocr Pract       Date:  2019-05-09       Impact factor: 3.701

3.  Is there a role for the IGF system and epidermal growth factor (EGF) in the pathogenesis of adrenocortical adenomas? A preliminary case-control study.

Authors:  I Lazúrová; I Jochmanová; Š Sotak; I Špaková; M Mareková
Journal:  Physiol Res       Date:  2020-11-19       Impact factor: 1.881

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.